Payment overview · 2025
General Payments
$1,512.04
56 reported records · 14 companies
Healthcare provider profile · identity verified
Tae J Noh, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TAMPA, FL · NPI 1750468914
Verified facts
What the public records show
CMS Open Payments records show Tae J Noh, M.D. received $1,512.04 in general payments during 2025 across 56 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $407.34 | 26.9% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $320.92 | 21.2% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $219.37 | 14.5% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $185.30 | 12.2% | 11 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $162.19 | 10.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.72 | 2.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.01 | 2.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.98 | 2.1% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $24.46 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.14 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.56 | 1.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.97 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.47 | 1.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.61 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,512.04 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $407.34 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $219.37 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $178.30 | 10 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $162.19 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $151.98 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $132.83 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $79.63 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.72 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.72 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.01 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $7.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 965 | 309 |
| Amlodipine Besylate | Amlodipine Besylate | 595 | 179 |
| Lisinopril | Lisinopril | 539 | 156 |
| Losartan Potassium | Losartan Potassium | 452 | 138 |
| Metformin Hcl | Metformin Hcl | 429 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 427 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 107 |
| Carvedilol | Carvedilol | 229 | 71 |
| Alprazolam | Alprazolam | 220 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 205 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 65 |
| Gabapentin | Gabapentin | 175 | 58 |
| Glimepiride | Glimepiride | 169 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 58 |
| Omeprazole | Omeprazole | 160 | 66 |
| Famotidine | Famotidine | 159 | 59 |
| Tramadol Hcl | Tramadol Hcl | 147 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 47 |
| Simvastatin | Simvastatin | 131 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 61 |
| Trazodone Hcl | Trazodone Hcl | 124 | 52 |
| Metformin Hcl Er | Metformin Hcl | 119 | 38 |
| Alendronate Sodium | Alendronate Sodium | 108 | 40 |
| Furosemide | Furosemide | 106 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 30 |
| Sertraline Hcl | Sertraline Hcl | 106 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 33 |
| Lorazepam | Lorazepam | 99 | 16 |
| Baclofen | Baclofen | 92 | 36 |
| Donepezil Hcl | Donepezil Hcl | 91 | 29 |
| Azelastine Hcl | Azelastine Hcl | 89 | 50 |
| Ezetimibe | Ezetimibe | 85 | 28 |
| Glipizide | Glipizide | 83 | 32 |
| Allopurinol | Allopurinol | 82 | 25 |
| Montelukast Sodium | Montelukast Sodium | 82 | 30 |
| Eliquis | Apixaban | 78 | 25 |
| Fenofibrate | Fenofibrate | 78 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 25 |
| Naproxen | Naproxen | 71 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 22 |
| Azithromycin | Azithromycin | 67 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 66 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 20 |
| Memantine Hcl | Memantine Hcl | 64 | 13 |
| Meloxicam | Meloxicam | 63 | 24 |
| Nifedipine Er | Nifedipine | 63 | 18 |
| Atenolol | Atenolol | 58 | 17 |
| Januvia | Sitagliptin Phosphate | 55 | 12 |
| Potassium Chloride | Potassium Chloride | 55 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 17 |
| Prednisone | Prednisone | 50 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 16 |
| Farxiga | Dapagliflozin Propanediol | 47 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 16 |
| Temazepam | Temazepam | 47 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | suppressed |
| Finasteride | Finasteride | 46 | 13 |
| Diazepam | Diazepam | 44 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 44 | 17 |
| Lovastatin | Lovastatin | 43 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 14 |
| Ozempic | Semaglutide | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 17 |
| Valsartan | Valsartan | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 11 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 18 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | 13 |
| Methocarbamol | Methocarbamol | 28 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 22 |
| Dilt-Xr | Diltiazem Hcl | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 11 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 21 |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | 16 |
| Hydrocortisone | Hydrocortisone | 21 | 15 |
| Torsemide | Torsemide | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 17 | 11 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Nystatin | Nystatin | 17 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 11 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 11 |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Fluconazole | Fluconazole | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Novolog | Insulin Aspart | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,512.04 · 56 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FUROSCIX, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, UPTRAVI, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error